These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29517501)

  • 1. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome.
    Cook HT
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):165-170. PubMed ID: 29517501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders.
    Turkmen K; Baloglu I; Ozer H
    Int Urol Nephrol; 2021 Oct; 53(10):2067-2080. PubMed ID: 33389509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Goodship TH; Cook HT; Fakhouri F; Fervenza FC; Frémeaux-Bacchi V; Kavanagh D; Nester CM; Noris M; Pickering MC; Rodríguez de Córdoba S; Roumenina LT; Sethi S; Smith RJ;
    Kidney Int; 2017 Mar; 91(3):539-551. PubMed ID: 27989322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
    Sethi S; Fervenza FC
    Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.
    Smith-Jackson K; Yang Y; Denton H; Pappworth IY; Cooke K; Barlow PN; Atkinson JP; Liszewski MK; Pickering MC; Kavanagh D; Cook HT; Marchbank KJ
    J Clin Invest; 2019 Mar; 129(3):1061-1075. PubMed ID: 30714990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
    Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
    Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?
    Ciocchini M; Musso CG
    Int Urol Nephrol; 2018 Jul; 50(7):1365-1366. PubMed ID: 29808447
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-complement-factor H-associated glomerulopathies.
    Durey MA; Sinha A; Togarsimalemath SK; Bagga A
    Nat Rev Nephrol; 2016 Sep; 12(9):563-78. PubMed ID: 27452363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
    Merinero HM; García SP; García-Fernández J; Arjona E; Tortajada A; Rodríguez de Córdoba S
    Kidney Int; 2018 Feb; 93(2):470-481. PubMed ID: 28941939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M; Emma F
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Osborne AJ; Breno M; Borsa NG; Bu F; Frémeaux-Bacchi V; Gale DP; van den Heuvel LP; Kavanagh D; Noris M; Pinto S; Rallapalli PM; Remuzzi G; Rodríguez de Cordoba S; Ruiz A; Smith RJH; Vieira-Martins P; Volokhina E; Wilson V; Goodship THJ; Perkins SJ
    J Immunol; 2018 Apr; 200(7):2464-2478. PubMed ID: 29500241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.
    Haydock L; Garneau AP; Tremblay L; Yen HY; Gao H; Harrisson R; Isenring P
    J Mol Med (Berl); 2022 Feb; 100(2):269-284. PubMed ID: 34714369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
    Ankawi GA; Clark WF
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28798244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement Inhibitors in Clinical Trials for Glomerular Diseases.
    Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C
    Front Immunol; 2019; 10():2166. PubMed ID: 31611870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor H Autoantibodies and Complement-Mediated Diseases.
    Zhang Y; Ghiringhelli Borsa N; Shao D; Dopler A; Jones MB; Meyer NC; Pitcher GR; Taylor AO; Nester CM; Schmidt CQ; Smith RJH
    Front Immunol; 2020; 11():607211. PubMed ID: 33384694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition.
    Hanna RM; Barsoum M; Vandross A; Kurtz I; Burwick R
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):278-287. PubMed ID: 30865166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].
    Yurova VA; Kozlovskaya NL; Bobrova LA; Kozlov LV; Andina SS; Demyanova KA
    Ter Arkh; 2023 Aug; 95(6):475-480. PubMed ID: 38158966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Perkins SJ
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):120-127.e4. PubMed ID: 32553244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.